Allergy immunotherapy Market Share

Global Allergy Immunotherapy Market Overview

The Allergy Immunotherapy Market Size was valued at USD 2.61 billion in 2023 and is projected to grow from USD 2.83 Billion in 2024 to USD 6.38 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.43% during the forecast period (2024 - 2032). 

The market is expanding due to rising demand for various medications to cure illnesses. Companies are working on the research component to create the medications they require on the market to meet demand. Also, market drivers such as key competitors producing an increasing number of anti-allergic pills will propel market growth.

In October 2023, Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs), and disease management solutions announced it had developed iPUMP®, the first connected allergy assistant, which was recently launched in France by Stallergenes Greer, a global healthcare company specializing in Allergen Immunotherapy Treatment (AIT). Designed for patients treated with Stallergenes Greer’s liquid sublingual AITs, the availability of iPUMP® followed a pilot phase conducted by Stallergenes Greer during which 92% of patients systematically used iPUMP® while taking their treatment.

In October 2023, Angany Inc. announced that it had received clearance from the U.K.'s Medicines and Healthcare Products Regulatory Agency for the first clinical study to be conducted on its vaccine candidate ANG-101 to treat human allergy to cats. ANG-101 is a therapeutic vaccine that provides a disruptive disease-modifying approach for treating cat allergy. 

Derived from its proprietary eBioparticle-Potentiated Immunotherapy™ technology, ANG-101 active immunotherapeutic ingredient is a unique 140 nm enveloped bioparticle (eBioparticle™) that mimics a virus in shape and size with its surface covered with thousands of copies of cat major allergen Fel d 1. This clinical study is a first-in-human, open-label, and single-site evaluation of the new vaccine's safety, allergenicity, and immunogenicity in adult patients allergic to cat dander.

In February 2023, Nectar Life Sciences, an allergy-focused healthcare holding company announced the launch of its innovative comprehensive allergy care platform, Nectar. The first product offering from the company’s allergy treatment program, Nectar Allergy Drops, is personalized, industry-proven sublingual immunotherapy drops that provide life-long relief from allergies by treating the root cause. 

Custom-formulated for each user, Nectar Allergy Drops provide a proven, effective, and convenient alternative to allergy shots and antihistamines for patients who suffer from moderate and severe indoor and outdoor allergies. Starting with a CLIA-certified allergy test and easy-to-understand instructions, users mail a blood spot card back to Nectar, and allergy results are available online two to three weeks later. The initial Nectar Allergy Test Kit is $199.

The market is growing as a result of the increased need for different pharmaceuticals to treat ailments. Companies are putting effort into the research needed to produce the medicines needed to satisfy market demand. Market expansion will also be fueled by market drivers including major rivals manufacturing more anti-allergic medications.

The burden of allergic illnesses, which are on the rise, may be connected to the anticipated growth in wealth. Complex allergies' financial and medical impact on the healthcare system drives research and development in this field to develop new treatments. In addition, as indoor and outdoor air pollution levels have risen, so has the prevalence of respiratory disorders including asthma and allergies.

Throughout the anticipated period, there is potential for market expansion of allergy immunotherapy due to consumers' increasing disposable incomes and their capacity to spend more on allergy-related therapies. It is growing quickly. Due to rising environmental pollution, increased alcohol use, modifications in diet and lifestyle, and an increase in allergies connected to the skin, the market for allergy immunotherapy has experienced a boom in demand.

Allergy Immunotherapy Market Trends

• Rising Prevalence of Allergic Disorders to boost the market growth

The predicted increase in income might be related to the burden of allergy illnesses, which is becoming more prevalent ly. The burden that complex allergies with increased morbidity place on the healthcare system motivate R&D in this area to introduce novel medicines. In addition, the prevalence of asthma and allergy respiratory illnesses has increased due to rising air pollution levels inside and outside. According to the Asthma and Allergy Association of America (AAFA), rising pollen levels cause more than 25 million allergies.

According to the Canadian Allergy, Asthma, and Immunology Foundation, between 20 and 25 percent of Canadians suffer from allergic rhinitis. Moreover, traditional symptomatic drugs are ineffective in treating 50% of the affected individuals. As a result, major corporations are concentrating on creating novel immunotherapy medicines. As an illustration, in 2019, ALK filed to the Canadian regulatory agency for its experimental tree SLIT-tablet. Many R&D efforts are being made by other businesses to produce immunotherapy treatments for food allergies. 

For example, Aimmune Therapeutics is creating the biologic immunotherapy experimental medication AR101 for peanut allergy. In clinical studies, the product was evaluated by more than a thousand people. Additionally, the FDA has accepted the product's 2019 biologics licence application (BLA) and is currently reviewing it. Also, a robust pipeline of immunotherapy treatment medicines is anticipated to offer businesses growth opportunities in the upcoming years. Sublingual immunotherapy has been studied for several food allergies, including milk, peanuts, kiwis, and peaches. According to the studies, the treatment is effective when the patient regularly takes their prescription. 

Unfortunately, it is still unknown how therapy will affect patients after treatment. Therefore, such applications in advanced treating conditions have recently enhanced the market CAGR of Allergy Immunotherapy.

With consumers' disposable incomes rising and their ability to spend more on allergy-related therapies, there is potential for market growth of allergy immunotherapy throughout the projected period. It is rapidly expanding. The  market for allergic immunotherapy has seen a surge in demand due to increased environmental pollution, higher alcohol use, changes in food and lifestyle, and an increase in skin-related allergies, contributing to the Allergy Immunotherapy market revenue.

Allergy Immunotherapy Market Segment Insights

Allergy Immunotherapy Treatment Insights

Based on treatment, the  market segments of Allergy Immunotherapy includes sublingual immunotherapy, subcutaneous immunotherapy, and specific immunotherapy. The sublingual immunotherapy segment held the majority share in 2022, contributing to around ~55-57% of the  Allergy Immunotherapy market revenue. This therapy can treat asthma, stinging insect hypersensitivity, and allergic rhinitis effectively. Moreover, SCIT has shown success in managing a variety of allergens. As a result, SCIT is more widely adopted than SLIT. The segment for sublingual immunotherapy (SLIT) is anticipated to have the quickest CAGR throughout the projection period. 

For individuals who cannot receive allergy injections, SLIT is anticipated to become an essential option. SLIT pills that have received FDA approval and are currently available in the United States include Odactra, Grazax, Oralair, and Ragwitek. It is anticipated that liquid formulation will also be authorized for therapeutic use in the United States. This would accelerate the development of the SLIT market in the nation.

June 2022 For adult patients with peanut allergies, Intrommune Therapeutics, Inc., a clinical biotechnology company with headquarters in New York, is currently developing INT 301. It is a patient-friendly treatment platform for peanut and other food allergies that proclaimed modifications to the OMEGA Phase 1 clinical studies. The patient's research term will now be 48 weeks long and include a maintenance phase. The safety of INT301 is being evaluated during this maintenance window.

June 2022 With cutting-edge Point of Care technology, QHSLab, Inc., a top provider of physician licensing and management services, aims to give doctors the tools they need to implement proactive, value-based healthcare solutions.

Figure 1  Allergy Immunotherapy Market, by Treatment, 2022 & 2030 (USD Million)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Allergy Immunotherapy Allergy Type Insights

The  Allergy Immunotherapy market segmentation, based on allergy type, includes allergic rhinitis, allergic asthma, peanut allergy, cat allergy, and others. Allergic rhinitis dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. Asthma affects 24 million Americans, including 6 million children, according to data from the American College of Allergy, Asthma & Immunology. 

Also, according to the figures, 50 million Americans suffer from an allergy each year. Consequently, it is anticipated that the market will experience profitable expansion due to the increasing disease burden caused by allergic disorders. Hence, rising applications for Allergy Immunotherapy positively impact the market growth.

Allergy Immunotherapy Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The Europe Allergy Immunotherapy market accounted for USD 1.1 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. It is anticipated to maintain its position over the projection period. The substantial presence of top market players, including ASIT Biotech, Circassia, Mylan N.V., and Merck KGaA, can be credited for this.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

July 2023: A recent study funded by the National Institutes of Health (NIH) in July 2023 demonstrates a promising experimental strategy that boosts the efficiency and speed of current cat allergy treatments. The study, which was published in the Journal of Allergy and Clinical Immunology, emphasizes the need for quicker and better treatment options. 

Researchers conducted a clinical trial to see if combining tezepelumab, a monoclonal antibody, with cat allergy shots would result in a more secure, efficient, and long-lasting symptom relief. Sneezing, runny nose, and itchy eyes are signs of allergic rhinitis, an inflammation of the nasal membranes.

July 2023: After Intrommune Therapeutics finished the last patient's final visit in July 2023, the Atrial investigation into desensitization immunotherapy administered as toothpaste for adults with peanut allergy attained a final milestone. In the Phase I OMEGA clinical trial (NCT04603300), 32 people with peanut allergies were divided into two groups and given escalating doses of the company's candidate INT301 or a placebo. 

This was a multi-center, randomised, placebo-controlled, double-blind study. The oral mucosal immunotherapy (OMIT) platform is used by Intrommune Therapeutics' candidate to administer the medication in fully functional toothpaste. OMIT's straightforward administration

Figure 2  ALLERGY IMMUNOTHERAPY MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

North America Allergy Immunotherapy market accounts for the second-largest market share because more than 150 million people in the United States have allergic illnesses. By 2025, it is predicted that more than 50% of the region's population will have at least one type of allergy due to several factors, including industrialization, urbanization, climate change, and pollution. Further, the Germany market of allergy immunotherapy held the largest market share, and the UK market of allergy immunotherapy was the fastest-growing market in the European region

The Asia-Pacific Allergy Immunotherapy Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to an increase in the number of allergy drops approved in Europe, which also increases the region's share. The use of allergy immunotherapy has been adopted differently throughout Europe and North America, as well as similarly. There are variations in the formulation, availability, and adoption of allergen extracts. Moreover, China market of allergy immunotherapy held the largest market share, and the India market of allergy immunotherapy was the fastest growing market in the Asia-Pacific region

For instance, India market of allergy immunotherapy will grow with the fastest growing CAGR in Asia Pacific during the forecast period. Primary factors propelling the regional allergy immunotherapy market are the expansion of industrialization and population, improvements in healthcare and medicine, and the launch of new immunotherapeutic medications. To increase the market share of the Indian allergy immunotherapy market, recent regulatory approvals, such as those for oral dissolvable tablets, are further enhanced.

Allergy Immunotherapy Key Market Players & Competitive Insights

Major market players are increasing their spending in their research and development departments to diversify their product portfolios. Additionally, the market leaders are employing vast market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Allergy Immunotherapy industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the  Allergy Immunotherapy industry to benefit clients and expand the market sector. In recent years, Allergy Immunotherapy industry has provided medicine with some of the most significant benefits. The Allergy Immunotherapy market major player such as ALK Abello (U.K.), Allergy Therapeutics (U.K.), Circassia (U.K.), DVB Technologies (U.K.), and others are working on expanding the market demand by investing in research and development activities.

The pharmaceutical firm ALK-Abelló A/S, also known as ALK, is situated in Denmark and specializes in developing and producing allergy immunotherapy (AIT) medicines to prevent and treat allergies. With 81% of its income from European sales, it is one of the biggest producers of allergy immunotherapy medicines (also known as "allergy vaccinations"). Later, the business became known as Allergologisk Laboratorium Copenhagen. Since then, the company has focused on mapping how allergies affect the immune system to create new, more effective treatments. The study focuses on hay fever and asthma in particular, as well as the prevention, treatment, and management of allergies. Abello Pharmaceuticals was created in Spain in 1925 by Juan Abello Pascual.

A pharmaceutical firm, HAL Allergy Group, creates, manufactures, and markets medicines for allergen immunotherapy and allergy diagnostics (AIT). The Leiden Bio Science Park in the Netherlands has headquarters and research facilities. The discovery, manufacture, and distribution of allergen immunotherapies for the treatment and prevention of allergic disorders have been the main focus since 1959. These immunotherapies generally treat common allergies like hay fever, house dust mite allergy, and allergic reactions to wasps or bee stings. They are administered subcutaneously (SCIT) or sublingually (SLIT). HAL Allergy is one of the main European competitors, especially in the allergy market, with offices in powerful European nations.

Key Companies in the market of Allergy Immunotherapy include

• ALK Abello (U.K.)


• Allergy Therapeutics (U.K.)


• Circassia (U.K.)


• DVB Technologies (U.K.)


• HAL Allergy Group (U.K.)


• Merck KGaA Allergopharma (U.K.)


• Stallergenes Greer (U.K.), among others

Allergy Immunotherapy Industry Developments

June 2022 The favorable findings regarding the significant advantage of sublingual liquid allergen immunotherapy treatment (AIT) on the beginning and worsening of asthma in patients with allergic rhinitis were released by Stallergenes Greer. This worldwide healthcare firm specializes in allergen immunotherapy (AIT).

March 2022 PVX108, a cutting-edge immunotherapy for treating peanut allergy, has begun Phase 2 clinical trials, according to an announcement from Aravax Pty Ltd.

Allergy Immunotherapy Market Segmentation

Allergy Immunotherapy Treatment Outlook (USD Billion, 2019-2030)

• Sublingual Immunotherapy


• Subcutaneous Immunotherapy


• Specific Immunotherapy

Allergy Immunotherapy Allergy Type Outlook (USD Billion, 2019-2030)

• Allergic Rhinitis


• Allergic Asthma


• Peanut Allergy


• Cat Allergy


• Others

Allergy Immunotherapy Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America